Ionis Pharmaceuticals (IONS) announces a private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024. To read this news go to the original content to download multimedia by clicking here.
During the announcement of 2019 third-quarter financial results the conference call started citing the firm's improved revenues and income. Revenues have increased by more than 50% to nearly $630 million and its guidance increased the year 2019 revenue to $1 billion from $725 while significantly improved its operating income and net income guidance.
About its products: Spinraza, Tegsedi and Waylivra . . .